Explore Tangramed's latest scientific insights, strategic collaborations and corporate developments at the intersection of AI-enabled drug discovery and multimodal therapeutics.
A published Phase III trial in China met its primary endpoint for PXT3003 in CMT1A, highlighting promising functional outcomes and the pioneering multimodal therapy expertise of Tangramed's scientific leadership.
Tangramed Biotech and Biomunex Pharmaceuticals are collaborating to identify and prioritize novel oncology target combinations through AI-enabled drug discovery.